GENE ONLINE|News &
Opinion
Blog

2022-09-29| Trials & Approvals

Sanofi and Regeneron’s Dupixent Snags its Tenth Approval From the FDA

by Reed Slater
Share To
Dupixent, the monoclonal antibody jointly developed by Sanofi and Regeneron, is keeping its momentum going with its third FDA-approved indication this year and its tenth since 2017. The latest indication is reserved for adults with the chronic skin disease, prurigo nodularis, making it the first and only drug indicated for the disease. The FDA based its decision on two Phase 3 trials demonstrating clinically significant positive data. 

It's free! Log in now to read

LOG IN SUBSCRIBE NOW
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top